$-0.23 EPS Expected for Daré Bioscience, Inc. (DARE)

July 14, 2018 - By Catherine Diaz

Analysts expect Daré Bioscience, Inc. (NASDAQ:DARE) to report $-0.23 EPS on August, 13.They anticipate $1.19 EPS change or 83.80 % from last quarter’s $-1.42 EPS. After having $-0.28 EPS previously, Daré Bioscience, Inc.’s analysts see -17.86 % EPS growth. The stock increased 0.78% or $0.01 during the last trading session, reaching $1.3. About 95,834 shares traded. Daré Bioscience, Inc. (NASDAQ:DARE) has declined 72.20% since July 14, 2017 and is downtrending. It has underperformed by 84.77% the S&P500.

Daré Bioscience, Inc. develops and commercializes product for women’s reproductive health, Ovaprene. The company has market cap of $14.85 million.

Another recent and important Daré Bioscience, Inc. (NASDAQ:DARE) news was published by Investingnews.com which published an article titled: “Biotech Update: Q2 2018 in Review” on July 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.